Enliven Therapeutics, Inc.
ELVN
$19.80
$0.110.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.48M | 19.83M | 17.36M | 15.23M | 15.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.25M | 97.79M | 93.67M | 87.90M | 79.63M |
| Operating Income | -103.25M | -97.79M | -93.67M | -87.90M | -79.63M |
| Income Before Tax | -88.79M | -84.98M | -82.60M | -79.60M | -71.58M |
| Income Tax Expenses | 232.00K | 232.00K | 232.00K | -- | -- |
| Earnings from Continuing Operations | -89.02 | -85.21 | -82.83 | -79.60 | -71.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -89.02M | -85.21M | -82.83M | -79.60M | -71.58M |
| EBIT | -103.25M | -97.79M | -93.67M | -87.90M | -79.63M |
| EBITDA | -102.94M | -97.47M | -93.35M | -87.59M | -79.33M |
| EPS Basic | -1.90 | -1.91 | -1.93 | -1.93 | -2.18 |
| Normalized Basic EPS | -1.18 | -1.15 | -1.15 | -1.13 | -1.30 |
| EPS Diluted | -1.90 | -1.91 | -1.93 | -1.93 | -2.18 |
| Normalized Diluted EPS | -1.18 | -1.15 | -1.15 | -1.13 | -1.30 |
| Average Basic Shares Outstanding | 188.25M | 179.52M | 172.28M | 165.17M | 141.63M |
| Average Diluted Shares Outstanding | 188.25M | 179.52M | 172.28M | 165.17M | 141.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |